Splash acquired exclusive global rights to CannEpil, a cannabinoid therapy for drug-resistant epilepsy, and secured a $1 million strategic investment to support U.S. development.
Key Highlights:
- Entered exclusive worldwide licensing agreement with Argent BioPharma for CannEpil to treat drug-resistant epilepsy.
- CannEpil has established access and reimbursement in multiple markets (Ireland, UK, Germany, Australia) and EU-GMP manufacturing.
- Program has an IND and has initiated pre-IND engagement with the FDA, underpinning potential U.S. clinical development.
- Received $1 million commitment from C/M Capital Partners to fund regulatory, clinical planning and commercialization activities.
- Consideration includes forgiveness of ~$5M Argent debt and issuance of $5.5M in newly issued preferred equity; Argent retains 15% royalty on net sales.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.